Dermomat is a regenerative medicine and biomaterials company developing innovative solutions for the treatment of chronic, non-healing wounds, particularly diabetic foot ulcers and other complex skin defects. The company was founded to address a significant unmet clinical need, as millions of patients worldwide suffer from wounds that fail to heal using conventional treatments, often resulting in infection, prolonged hospitalisation, reduced quality of life, and limb amputation.

At the core of Dermomat's technology is a mechanotransduced antibacterial skin scaffold designed to actively promote tissue regeneration while simultaneously protecting against infection. Unlike traditional wound dressings that provide passive wound coverage, Dermomat's biomimetic platform interacts with cells and the wound microenvironment to stimulate healing, encourage blood vessel formation, and support the restoration of healthy tissue.

The company's technology combines advanced biomaterials engineering, extracellular matrix-inspired design, and regenerative medicine principles to create clinically relevant and scalable products. Dermomat aims to develop cost-effective therapies that improve patient outcomes while reducing the economic burden associated with chronic wound care.

Operating at the intersection of healthcare, biotechnology, and tissue engineering, Dermomat is focused on translating cutting-edge scientific research into practical medical solutions. Through strategic partnerships with clinicians, healthcare providers, researchers, and industry collaborators, the company seeks to accelerate product development and commercialisation. Dermomat's long-term vision is to become a leader in regenerative wound care, delivering transformative technologies that improve healing outcomes and enhance the lives of patients worldwide.

Dermomat

Org chart

Teams

Offices

Dermomat

Org chart

Teams

Offices

Related companies